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Abstract
Pharmacovigilance plays a key role in the healthcare domain through the assessment, monitoring and discovery of
interactions amongst drugs and their effects in the human organism. However, technological advances in this field
have been slowing down over the last decade due to miscellaneous legal, ethical and methodological constraints.
Pharmaceutical companies started to realize that collaborative and integrative approaches boost current drug
research and development processes. Hence, new strategies are required to connect researchers, datasets,
biomedical knowledge and analysis algorithms, allowing them to fully exploit the true value behind state-of-the-art
pharmacovigilance efforts. This manuscript introduces a new platform directed towards pharmacovigilance
knowledge providers. This system, based on a service-oriented architecture, adopts a plugin-based approach to
solve fundamental pharmacovigilance software challenges. With the wealth of collected clinical and pharmaceutical
data, it is now possible to connect knowledge providers’ analysis and exploration algorithms with real data. As a
result, new strategies allow a faster identification of high-risk interactions between marketed drugs and adverse
events, and enable the automated uncovering of scientific evidence behind them. With this architecture, the
pharmacovigilance field has a new platform to coordinate large-scale drug evaluation efforts in a unique ecosystem,
publicly available at http://bioinformatics.ua.pt/euadr/.
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Introduction
Pharmacovigilance plays an essential role in the post-market
analysis of newly developed drugs [1, 2]. Pharmaceutical
companies' competition along with rigorous regulatory
evaluation procedures empowers a complex research and
development process before launching a new drug into the
market. Notwithstanding, drug safety continues to be a relevant
concern for healthcare involving worldwide policy stakeholders,
from regulatory health authorities to specialised law firms. Post-
market pharmacovigilance complements the traditional pre-
market austere drug approval process, where the European
Medicines Agency (EMA) [3] and the US Food and Drug
Administration (FDA) [4] establish guidelines for new medicine
approval, requiring intense testing and trials [5]. Along with
these recommendations, pharmaceutical companies must also
define thorough risk management plans for post-market drug
stages [6, 7].
Pharmacovigilance research is based on the analysis of
"signals". The World Health Organization (WHO) defines
signals as undisclosed assertions on direct relationships
between adverse events – effects on the human organism -
and a drug [8]. To generate comprehensive signal datasets,
clinicians and researchers use spontaneous reporting systems
(SRS). Electronic SRSs are already in place throughout some
European countries and the USA. Likewise, other solutions,
such as general practitioners’ databases analysis, post market
studies or prescription monitoring, among others, are being
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thoroughly explored. Nevertheless, the majority of data is not
publicly available for researchers, which, jointly with other
barriers, severely limits signal detection [9, 10].
Although drug companies are required to track and manage
adverse events reported by clinicians, lawyers or patients, the
detection process relies mostly on the physician's ability to
recognise a given trait as a drug adverse event. In addition to
this underreporting, results are also biased due to selective
reporting (reporting only certain drugs or conditions), placing
the threshold of reported ADRs between 1-10% [11-13].
Whereas the problem for collecting and filtering ADR data
from multiple distributed nodes has already been studied in the
past [14], researchers continue to pursuit the best strategies to
delve into the wealth of collected data in conjunction with other
post drug administration inputs. With data and text-mining
techniques scavenging millions of electronic medical records,
pharmacovigilance researchers are now faced with the problem
of delivering knowledge-oriented tools and services that exploit
the scope of collected data. Ultimately, the adequate
exploration of these data will pave the way for improved drug
evaluations, critical for pharmaceutical companies, regulatory
entities and researchers [15].
And herein lies the grand problem for contemporary
pharmacovigilance: how to enable any researcher to assess
and explore the wealth of collected data across a variety of
algorithms and tools? In summary, researchers need new
automated strategies to mechanistically understand the
scientific evidence behind specific drug and adverse event
interactions, through the processing of data mined from millions
of electronic medical records and analysed independently by
multiple algorithms. To overcome this problem, six key
challenges arise for researchers and developers.
• Scalability. Controlling a flexible amount of algorithms,
each providing independent access to knowledge, with its
independent set of features and offering access to closed
functionalities.
• Interoperability. The integration of multiple knowledge
providers requires that a solution akin to a "common language"
must be setup so that the various tools and algorithms can
interact with each other and with a central software
choreographer.
• Management. This brings two challengers: (1) how to store
and make the collected data available to all researchers, and
(2) how to organise and coordinate the set of available
knowledge providers.
• Reproducibility. The replication of all research steps,
including data and used knowledge providers must be available
for other researchers and for further auditing.
• Accessibility. All the data and features must be presented
in a unified workspace, publicly available to all interested
stakeholders.
• Security. At last, interactions between knowledge
providers, implemented software and researchers must be
established through secure channels.
The strategy introduced in this manuscript, and its underlying
architecture, implementation and prototype, successfully
covers the aforementioned challenges, introducing a
pioneering solution to deliver pharmacovigilance studies to
researchers worldwide.
Materials and Methods
Background
Large-scale projects such as Research on Adverse Drug
Events and Reports (RADAR) [16], Observational Medical
Outcomes Partnership (OMOP) , Mini-Sentinel [17] or
Exploring and Understanding Adverse Drug Reactions by
Integrative Mining of Clinical Records and Biomedical
Knowledge (EU-ADR) [18], among others, are pushing forward
innovative strategies to improve active pharmacovigilance
scenarios.
The RADAR project adopts a strategy where a highly
specialized team reviews incoming drug adverse reports.
Despite generating invaluable curated results, this approach
implies a large waste of intensive manual labour. In opposition,
OMOP, Mini-Sentinel and EU-ADR adopt more automated
strategies.
OMOP and EU-ADR share a common setup, where data
from partners are automatically collected, mined and analysed.
Partners’ data are translated to a common data model (CDM),
anonymized, summarized and imported into a central
integrative data repository for further statistical processing.
OMOP is applied to two distinct surveillance scenarios,
tackling the identification of well-known drug associations and
the identification of previously unknown signals [19]. This
identification is validated through the application of multiple
analytical procedures over a broad number of summarized
patient records. In fact, OMOP’s initial stage finished with an
assessment of the best methods to identify pharmaceutical risk
in healthcare data [20]. Selected algorithms are now being
applied in the project’s second stage.
EU-ADR distributed pipeline, discussed in detail in the
following section, is very similar to OMOP’s. The major
difference resides on the partners’ data. Whereas in OMOP
most data stems from private contractors in the United States
of America, in EU-ADR, data are obtained from European
nationwide registries. Regarding the statistical analysis, EU-
ADR’s core longitudinal observation algorithms are LGPS and
LEOPARD [21].
Despite featuring a distributed architecture, Mini-Sentinel is
very different from the setup used in OMOP and EU-ADR.
Whereas in the latter projects data are summarized and
submitted for statistical analysis, in Mini-Sentinel data queries
go through a complex network [22]. Like similar projects,
partners in the Mini-Sentinel program translate their dataset to
the project’s CDM. However, in Mini-Sentinel, data never
leaves the original institution [23]. This addresses FDA’s
concerns regarding security and privacy.
With Mini-Sentinel’s strategy, data queries are “executable
programs” that are sent to partners for in-premises execution
[24]. Once queries are received, partners can analyse
requested data, execute them and validate the results before
reporting to the query authors. Mini-Sentinel’s project
coordination then assembles generated results and transfers
summary data to the query authors. In spite of being more
Exploring Knowledge in Pharmacovigilance
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secure, this strategy can lead to delays in query answering,
specially considering the project’s 7-day average response
time.
With most of these projects in their infancy, a correct
assessment of their results is a long-term task. Nevertheless,
comparison frameworks are being put in place to better
evaluate and compare the qualitative results of each project
[25].
The EU-ADR Project
The foundation for EU-ADR's strategy relies on in-depth
semantic data mining of electronic health records from several
European countries. This process generates filtered data that
can be easily substantiated through distributed computational
tools [26] – Figure 1.
Project partners provide demographics, drug use and clinical
data for over 20 million patients from several European
countries. These data include clinical history, drug
prescriptions, vaccinations, or lab test results [27, 28]. From a
pharmacovigilance perspective and in a European or worldwide
scale, mining the amount and type of data collected in these
databases is of tremendous importance for an improved post-
marketing drug evaluation [29].
Data mining techniques are used to extract the most relevant
information from these data sources [30, 31], taking in account
the privacy and ethical concerns regarding the collected data
[32]. Next, data are harmonized into a unified dataset
containing the list of drug-event pairs identified in the mined
records [33]. This initial detection process generates a raw
signal list, as the signal detection techniques highlight all
possible relationships discovered in the wealth of collected
data [34] – Figure 1-1.
As mentioned, the creation of these rich signal datasets is a
well-established task. However, the actual data analysis and
exploration tasks are still missing. Each signal in the raw list
provided by the data mining tools must be substantiated for
adequate validation. That is, the signal must be analysed by
multiple algorithms to identify its real risk, and, if it exists, to
provide a scientific explanation behind the cause, the drug, and
the effect, a specific adverse reaction. This step, highlighted in
Figure 1-2, differentiates the EU-ADR project pipeline from
other related projects.
The signal substantiation algorithms can range from simple
literature analysis, to drug target interaction matching. This is
the key pharmacovigilance challenge to the EU-ADR project:
how to design an architecture that can leverage on the data
acquired from millions of electronic health records by
enhancing its automated evaluation through any number and
kind of distributed algorithms?
At last, results for these algorithms must be easily available
for researchers [35] – Figure 1-3. The data flow ends at the
researchers’ workspace, where they can validate the system,
explore the resulting scientific evidence and, if required,
proceed to take the necessary steps to prevent new
occurrences for the high-risk drug event interactions.
A Distributed Pharmacovigilance Platform
The architecture of a distributed platform in the context of
pharmacovigilance must tackle the six mentioned challenges -
scalability, interoperability, management, reproducibility,
accessibility and security. The proposed service-oriented
architecture is shown in Figure 2 and its components described
in Table 1.
This architecture is built on top of multiple interactions,
exploiting the components’ dynamics. Results from the
semantic harmonization of mined records, the raw signal list,
are securely stored on the knowledge base, being easily
accessible to all the other components. Once the users select
the knowledge providers from the provider registry, the data
are transmitted to the service execution engine, which then
contacts each of the knowledge providers for service
execution. The outputs of the analysis algorithms are next
stored in the platform’s knowledge base, and delivered to the
researchers through the web application engine. All these
interactions are controlled and securely mediated by the
application engine.
Scalability & Interoperability.  The provider registry and the
service execution engine ensure scalability and interoperability.
Figure 1.  EU-ADR initiative data flow.  1) Data extracted from electronic health record (EHR) resources are semantically
harmonized for data mining, generating a raw drug-event pair list. 2) The signal substantiation process analyses the submitted data,
re-ranking the signal list, based on multiple algorithms. 3) Users trigger data analysis and exploration to validate the system
operability.
doi: 10.1371/journal.pone.0083016.g001
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To completely remove any interdependence amongst
knowledge providers, a common data description and
exchange language was created. Additionally, to foster the
seamless integration of knowledge providers, data input and
output formats must be compatible.
A new XML schema (XSD) was designed to accomplish this.
The flexibility of XSD enables the validation of both content and
structure, preventing erroneous data transfers and reinforcing
the overall platform robustness. The schema structure is
divided in three main sections, each focusing on one operability
perspective.
• Monitoring. Real-world use of knowledge providers can
result in an assorted amount of errors: general communication
errors, such as failure to connect to a database, or domain-
specific errors, such as invalid data. Therefore, the created
Figure 2.  General architecture for the distributed pharmacovigilance platform.  
doi: 10.1371/journal.pone.0083016.g002
Table 1. Architecture component descriptions, implementation and operability purpose.
Component Operability   Implementation Description
Service execution
engine External Java Taverna
With each knowledge provider delivering service-based access to its algorithm, the service execution engine is
responsible for performing the service calls with the input data read from the knowledge base and retrieving the
output data towards the platform.
Knowledge base Internal Cloud-based
The knowledge base stores all relevant data from the integrated and imported pharmacovigilance datasets. Data
are stored in a cloud-based environment, moving the inherent complexities associated with secure data storage
to en efficient cloud provider.
Provider registry Internal Java The provider registry acts as the main knowledge provider controller. This is where new knowledge providersmust register their interfaces and endpoints so that they can be made available for future use.
Knowledge
Providers External
Independent XML-
based standard
The knowledge providers deliver independent access to various pharmacovigilance data analysis and
exploration algorithms. Access to knowledge providers is service-based.
Platform engine Internal Java The platform engine is the architecture core component, where all the tasks are executed and the interactionscontrolled.
Web engine Internal Google Web Toolkit The web engine powers the distributed platform user interactions through an innovative web-based workspace.
doi: 10.1371/journal.pone.0083016.t001
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schema covers the domain-specific errors with a set of “status
codes” for each of the possible conditions. For example, status
code with the value “41” identifies an internal service problem
regarding the database connection.
• Scoring. Each of the signals in the ranked list has a score
that determines its relevant risk within the dataset. When the
data are being assessed by the knowledge providers, the
scoring attributes will provide each evaluated signal with a
numeric value, between 0 (zero) and 1 (one), measuring the
relative relevance and impact according to the scientific
evidence found to explain the interactions of a given drug-event
pair.
• Annotation. When a scientific explanation is found for a
given set of drug-event pairs, the output is annotated with
reliable evidence for the interaction, providing researchers with
valuable knowledge and allowing them to evaluate the signal,
share the results and reproduce their research in the future.
These annotations appear in the form of connections to
relevant resources, such as literature (PubMed links), proteins
(UniProt links), chemical compounds (SMILE codes) or
pathways (Reactome links), among others.
The schema is available online (http://bioinformatics.ua.pt/
euadr/euadr_types.xsd), enabling anyone to create and add
new algorithms to this plugin-based distributed platform, thus
becoming one of the project's knowledge providers.
Knowledge Providers.  Interoperability amongst various
knowledge providers required the design of a strategy to
explore the true value of the created data exchange standard.
Whilst the schema is an essential component of the distributed
platform interoperability features, it is useless by itself: the
execution of knowledge providers’ algorithms must be
intermediated by a distinct component, the service execution
engine.
Another drawback regarding the implementation of
knowledge providers relates to their internal algorithms.
Whereas in some cases the algorithms are relatively
straightforward, in the majority of scenarios the algorithms
require multiple service-service interactions and data
processing tasks.
This added another complexity layer to our architecture: the
knowledge providers required heterogeneous interactions
within their algorithms, a challenge that could not be tackled at
the distributed platform level. Hence, the use of scientific
workflows arises as a solution [36]. A crucial workflow
requirement is that the inputs of each activity must match the
precedent activity outputs to maintain consistency, a feature
already accomplished with the platform interoperability
standard. Dealing with workflow execution operations requires
the implementation of workflow management applications,
whose goal is to abstract the programming side of the
application, assisting in the creation of workflows without
writing a single line of code [37].
Taverna emerged as the de facto standard for desktop-
based workflow management in the life sciences [38].
Taverna’s success is due to its flexibility, which allows
researchers to create complex workflow-based algorithms just
by dragging and dropping boxes in its workbench. Alternatives
to Taverna, such as Galaxy [39] or BioFlow [40], are focused
on providing workflow management functionality in a web-
based interface. However, this was not a requirement for our
scenario and, at the time of development, these tools do not
offer an API as advanced as Taverna’s.
With Taverna in place, the provider registry collects
metadata for Taverna workflows, and contains algorithms that
can be downloaded for local use or executed online in the
distributed platform. In addition to maintaining a list of available
workflows, Taverna’s integration also required the
implementation of a service execution engine. This solution
allows the combination of comprehensive data analysis and
exploration algorithms within the distributed platform. In
summary, we need to feed the workflows with XML input data,
execute them and extract the resulting data from the XML
output. Figure 3 illustrates the steps required to execute
knowledge providers’ workflows.
The service execution engine is a Java tool built to execute
Taverna’s command line interface with custom input
arguments. These parameterized system calls run in their own
independent OS process, increasing the overall platform
performance and scalability. Workflow executions are also a
background non-blocking asynchronous process. For
researchers, this means that they can use all the application
features whilst the workflows are being executed in the
background.
Knowledge Management.  The adequate management of
scientific data is critical to the success of the proposed
distributed pharmacovigilance platform. Not only we need to
consider how to make all relevant knowledge accessible at all
times, we also need to implement adequate data sharing
features: data must be exchanged between knowledge
providers and collaboration is one of the underlying premises
for research reproducibility.
The knowledge base is stored on a cloud environment [41].
This means that while the underlying data storage layer is
distributed through multiple independent data nodes, the
access is unified and centralized through a single access point.
Common data storage issues such as persistence, security and
access are controlled by the cloud-based layer, leaving the
relevant data handling tasks to the platform engine [42].
In the EU-ADR project context, five key datasets are stored,
detailed next.
• Drugs. Dataset containing the complete list of ATC codes
and respective drug names.
• Adverse events. Dataset listing the adverse events mined
from the project's pharmacovigilance data.
• Imported data. Researcher-submitted datasets containing
statistical data regarding specific drug-event mapping
conditions.
• Results. Datasets with the results from the knowledge
providers' algorithms.
• Users. Dataset containing the user details and sharing/
collaboration preferences.
Collaboration features are implemented according to two
distinct methods: project-based and ad hoc sharing. With the
project-based collaboration option, new projects with any
number of users can be configured. This allows a broad
Exploring Knowledge in Pharmacovigilance
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number of users to manage a topic-specific dataset, fostering a
deeper collaboration amongst researchers through the sharing
of submitted data and obtained results.
Ad hoc collaboration is a user-specific approach. Users can
share their datasets and results to any other user in the
platform through their registration email. This is a more
granular approach, where the users can define what data to
share and what their collaborators can view or change.
Accessibility.  Accessing knowledge and executing
available features are key challenges behind
pharmacovigilance software [43]: managed data and
knowledge providers' algorithms must be accessible at all
times. To accomplish this, the architecture relies on two
advanced components: the platform engine and the web
engine. The former is the main application controller,
coordinating all the others components. The latter manages the
presentation layer, providing access to a web-based
workspace. The implementation of both is detailed in Figure 4.
Taking into account the accessibility and interoperability
requirements, the platform engine is implemented as a Java
web application. For improved data handling, Hibernate (http://
www.hibernate.org/) was used as a data abstraction layer and
object/relational mapper, thus reducing database coupling with
the application. This shields the development from future
changes in the domain model storage system and eases the
use within the Java object-oriented environment.
Additional components were also used, such as Spring
Security (http://static.springsource.org/spring-security/site/) for
improved security features, Apache POI (http://poi.apache.org/)
for enhanced data import and export, Log4j for logging
purposes and Apache Maven (http://maven.apache.org/) for
project dependency management, building and deployment.
The platform engine mediates the interactions within the
distributed ecosystem. It controls the entire architecture and its
data flows, moving the data from the knowledge base towards
the service execution engine, establishing secure connections
in all transactions, and regulating the provider registry system,
among others. In a sense, the platform engine is an intelligent
proxy, coordinating everything that happens with the distributed
platform internal components.
The web application engine adopts a Model-View-Presenter
pattern and is implemented with the Google Web Toolkit
(GWT) framework (https://developers.google.com/web-toolkit/).
GWT compiles Java code to a browser-targeted JavaScript
representation, resulting in an extremely effective web
application. In addition, various user interaction components
were added to provide a cleaner perspective over the huge
datasets and easy access to data analysis and exploration
features. To improve on GWT’s user interactions library, the
Ext GWT package (GXT) (http://www.sencha.com/products/
gxt) was used. This extends the widgets bundled with GWT
core distribution to provide a more complete set of user
interaction features required by the presentation layer. The
combination of GWT’s basic widgets with GXT ones was
further improved with Google Gin (http://code.google.com/p/
google-gin/) for dependency injection, achieving a decoupled
architecture.
Security.  Security is a primary concern for any new
software, especially considering the rigorous constraints of this
field, for both researchers and private pharmaceutical
companies [44, 45]. In the proposed architecture, security
Figure 3.  From user input to system output the platform engine controls the execution of workflows as follows:.  1) One or
more knowledge provider algorithms are selected to evaluate researcher-submitted datasets. The platform engine sends the
request to the service execution engine. 2) An XML file with the input data (obeying the platform’s interoperability standard) is
generated and its path provided to the service execution engine, along with the path for the workflows associated with each
knowledge provider algorithm. The workflow execution is then triggered by a system call. 3) The Taverna command line tool loads
the knowledge provider’s workflow, starting the processing tasks. 4) The knowledge provider execution proceeds internally,
executing the miscellaneous workflow tasks. 5) The workflow delivers an XML data file (obeying the platform’s interoperability
standard) with the algorithm output. 6) The service execution engine loads the XML output file and transfers the results to the
platform engine. 7) The engine stores the data in the knowledge base and makes it promptly available for delivery in the web
workspace.
doi: 10.1371/journal.pone.0083016.g003
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measures are applied at three levels: interactions, data and
users.
All interactions within the distributed platform go through a
secure HTTP channel. Knowledge providers’ services must be
deployed in a HTTPS endpoint and the use of valid certificates
is enforced. However, this measure only secures the execution
of workflows within the service execution engine. Hence, in
addition to securing the knowledge providers, the implemented
architecture also delivers secure access to the web workspace,
which is served through and HTTPS channel.
At the data level, managed data are securely stored in the
knowledge base using encryption measures to obfuscate the
actual content. For instance, data owner details are used to
“salt” the data, further bolstering its illegibility. By using a cloud-
based approach, the logical storage is decoupled from the
physical storage, further improving the overall security.
Moreover, security and privacy features are delegated to the
cloud-based controller. Likewise, partner data introduced in the
system has already been carefully anonymized.
At last, on a user perspective, collaboration preferences can
be tightly controlled. The distributed platform collaboration
features facilitate granular data sharing, so that researchers
know whom they are sharing data with and how those data are
being used. Considering the sensible nature of the majority of
stored data, access to the web workspace requires registration
and all actions are tracked, assisting the monitoring of
everything that happens within the system.
Results
The pharmacovigilance context opens various opportunities
to build new data analysis and exploration ecosystems. With
collaboration from partners within the EU-ADR project it was
possible to implement a prototype of the proposed distributed
platform. The involvement in a large-scale European project
allowed for the implementation of real-world algorithms by
multiple knowledge providers. This partnership brought access
to a comprehensive dataset of drugs, events and statistical
data. The resulting EU-ADR Web Platform, is available online
at http://bioinformatics.ua.pt/euadr/. This portal is being used
within and beyond the EU-ADR project scope, generating
successful research results in various areas, such as the
identification of drug agents causing acute myocardial
infarction [46].
Pharmacovigilance Algorithms
The initial service-oriented architecture implementation
includes four knowledge providers, each with its own
pharmacovigilance algorithm and made available as a Taverna
workflow using secure services. The algorithms are deployed
independently in distinct physical and logical settings. The first
three algorithms provide a score, between 0 and 1, for each
input signal, marking whether or not there is scientific evidence
behind the drug-event pair.
The first algorithm, literature analysis, adopts a semantics-
based approach [47] that processes Medline annotations
looking for particular MeSH terms and metadata related to the
Figure 4.  Internal platform implementation software overview.  Used components are implemented in Java, leveraging the
open-source nature of this solution. 1) Platform engine components include Hibernate, JPA, Spring Security, POI, Log4j, Guice and
custom code to control the application and serve it as a Tomcat web application. 2) The Web engine relies on Google Web Toolkit
to generate a highly responsive web workspace. Add-ons such as GXT and Gin were used to improve the user interactions’
performance and reliability.
doi: 10.1371/journal.pone.0083016.g004
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submitted drug-event pair. Using the MeSH thesaurus,
matches for the subheadings “chemically induced” and
“adverse effects” are searched in associated publications. The
“Pharmacological Action” knowledge from MeSH thesaurus is
also used to refine the search.
When no matches are found, the partial scoring for the given
drug-event pair is 0 (zero). In the opposite, with 3 or more
publications found, the signal is scored with 1 (one). Between 0
and 3 (exclusive) publications, the partial score will be of 0.5.
Positive scores imply that scientific literature has been
published on the association between the drug and the event.
In these cases, the knowledge provider annotates the output
with PubMed ID links of the discovered publications.
The second strategy, involves a signal filtering co-occurrence
process, evaluating the relationships between drugs and side
effects that might have been reported previously in Medline
literature, DailyMed [48] or DrugBank [49]. Data from these
resources are previously indexed, including titles and abstracts
from Medline, summary product characteristics from DailyMed,
and ATC codes with potential adverse events from DrugBank.
The algorithm then performs a chi-square test to determine if
the co-occurrence of the given drug-event pair is different than
what would be expected by chance.
Similarly to the first algorithm, when interactions are found in
the indexed knowledge base, the signal gets a scoring of 1
(one). The annotation section of the output will include
identifiers and connections to the relevant resources (Medline,
DailyMed or DrugBank).
The third algorithm, signal substantiation, generates a
network based on the drug-event pair containing the
interactions with proteins targeted by the drug and associated
events, and with biological pathways [50]. This results in drug-
target and event-target profiles that are searched for common
sets of proteins, the intersecting portion of the graph.
The output of this algorithm, a comprehensive list of proteins
and pathways related to the drug-event pair, is annotated to the
knowledge provider output along with the partial signal
classification score.
Once the data are processed through these algorithms, the
results must be combined to better assess the plausibility of a
given drug-event relationship. The fourth algorithm, evidence
combination, uses the scores from the other knowledge
providers to arrive at a degree of belief that takes available
evidence into account. The algorithm uses the Dempster–
Shafer theory [51] to evaluate the initial data combined with
algorithm results to reach a measurable belief level that a
particular drug-event pair has a low, medium or high risk.
Algorithms weight and relevance in the final measurement can
be customized to better fit the research context. This final risk
measurement is the most important outcome of the performed
pharmacovigilance research as it summarizes the relative risk
for each drug-event pair in context of available knowledge.
These algorithms have been deployed independently by EU-
ADR project partners, which reinforce the proposed platform
suitability to environments requiring software interoperability.
Web Workspace
EU-ADR Web Platform’s key feature is the execution of
advanced post-marketing adverse drug reaction studies.
Researchers upload and investigate drug-event datasets,
create targeted drug studies and work with their peers through
the available collaboration features. Each researcher has its
own personal workspace, where they can browse existing
datasets (personal or shared); upload custom drug-event pair
datasets; or create drug-specific datasets, based on the overall
platform data.
A researcher interested in studying potential adverse
reactions of patients treated with a given drug, XYZ for the
purpose of this discussion, begins its study by automatically
generating a dataset focused on the targeted drug. The system
then combines this drug with the 11 potential adverse events
considered in EU-ADR’s context, evaluates the resulting
dataset using the available knowledge providers and combines
all individual pieces of evidence into an aggregate score
representing the predicted risk of each drug-event relationship
– Figure 5. Signals classified as moderately or highly risky
should be further investigated by analysing presented evidence
and following hyperlinks to biomedical literature, as well as to
external drug and biological data resources.
Conclusions
Despite the thorough research and development standards,
post-market pharmacovigilance plays a key role in the
assessment of existing medicines and creation of new drugs.
Nevertheless, research over the last decades has focused on
identifying and measuring specific adverse drug reactions in a
post-marketing stage [52-54]. The holistic assessment of
widespread electronic medical records empowers valuable
insights over adverse drug events. Notwithstanding the value of
these data per se, the development of new strategies to fully
exploit the scientific background regarding reported events is
vital.
This manuscript details the creation of such strategy,
proposing a pharmacovigilance-focused distributed platform
and introducing an open framework for the better exploration of
the wealth of available pharmacovigilance data by all
pharmacogenomics stakeholders. The EU-ADR Web Platform
is a unique tool that allows researchers to exploit the wealth of
data from a European cohort, combined with independent drug-
event datasets. In addition to being a step forward relative to
existing solutions [55], the designed strategy accurately tackles
multiple challenges behind the development of state-of-the-art
software within the pharmacovigilance domain: scalability,
interoperability, management, reproducibility, accessibility and
security.
• The plugin-based provider registry ensures that the
platform is scalable. Where the standard defines the
knowledge providers’ interfaces, the provider registry stores
metadata regarding the available algorithms, making them
available as workflows for local or remote execution.
• A new interoperability language was developed to ensure
that all knowledge providers understand the data being
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exchanged, enabling accurate interactions within the
distributed platform ecosystem.
• With knowledge providers managed through provider
registry, collected data are stored in a cloud environment,
streamlining the associated knowledge management tasks
[56].
• This proposal enables research reproducibility through the
collection of multiple datasets, which include easily
reproducible analysis results. This step is further improved
through the use of a cloud-based knowledge base, storing all
gathered and submitted data, and ensuring availability,
reliability and an eased access for all the architecture
components.
• The platform’s data analysis and exploration features are
accessible through a web interface, constantly available to
every researcher in any kind of system or device.
• This new architecture enforces the establishment of secure
communication channels amongst the platform and the
knowledge providers, the security of datasets and the restricted
web-based workspace.
A prototype implementation of this strategy is in place in the
context of the European EU-ADR project, extending the
interoperability amongst project partners. The EU-ADR Web
Platform connects distributed knowledge analysis algorithms,
and is available online for public use at http://
bioinformatics.ua.pt/euadr/.
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